Pharmacokinetic Study of Single and Repeated Dose of Roflumilast 500 µg , in Healthy Chinese Subjects

• Status: Completed
• Trial end date: 2011-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary objective is to assess the pharmacokinetics (PK) of roflumilast and its metabolite roflumilast N-oxide after single and repeated oral administrations of roflumilast 500 μg in healthy Chinese subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca

Criteria

Main Inclusion Criteria:

• Healthy male and female (24 male and 8 female) subjects of Chinese ethnic origin, age 40 years and older.

• Assessed as healthy based on a screening examination including medical history, physical examination, blood pressure, pulse rate, ECG assessment, and clinical laboratory results.

• Body weight according to a Body Mass Index (BMI) between 19 and 28 kg/[m²], (both inclusive) and a body weight ≥ 50 kg.

• Females with childbearing potential who are using medically acceptable and reliable method of contraception for the entire study duration, such as tubal ligation, hysterectomy, intrauterine device without hormones or post-menopausal females, the latter is defined as females who have had no menstrual period for at least 2 years.

Main Exclusion Criteria:

• History or current evidence of clinically relevant allergies or idiosyncrasy to drugs or food

• History of allergic reactions to roflumilast or any inactive ingredients of the trial medication

• History or current evidence of any clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other disease (within the last 2 years)

• History of malignancy within the past 5 years

• Electrocardiogram (ECG) abnormalities of clinical relevance (e.g. QTc according to Bazett's formula: QTc > 450 msec (male), QTc > 470 msec (female), PQ ≥ 220 msec)

• Blood pressure ≥ 140 mm HG systolic or ≥ 90 mm HG diastolic

• Elevated transaminases > 2 x upper Limit of normal range and or increased of the total bilirubin > 1.5 upper Limit of normal range

• Clinically relevant abnormalities in clinical chemical, hematological or any other laboratory variables

• Chronic or clinically relevant acute infections

• Proneness to orthostatic dysregulation, faintings, or blackouts

• Positive results in any of the virology tests of acute or chronic infectious HIV and hepatitis A, B, and C virus infections

• Positive drug screen

• Abuse of alcohol or drugs

• Positive β-HCG pregnancy test (female)

• Pregnant or lactating females